Press Releases

Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors

September 26, 2019
Macrophage Pharma Limited has appointed Dr. Anker Lundemose as independent non-executive director.
Read more
Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors

Macrophage Pharma appoints Dr Søren Bregenholt as Chief Executive Officer

September 03, 2019
Macrophage Pharma Limited ('MPL') announced today that it has appointed Dr Søren Bregenholt as Chief Executive Officer....
Read more
Macrophage Pharma appoints Dr Søren Bregenholt as Chief Executive Officer

Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer

August 01, 2019
Maastricht, The Netherlands, 1st August 2019 - Cristal Therapeutics, a Phase 2 clinical stage pharmaceutical company developing...
Read more
Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer

Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial

August 01, 2019
AMSTERDAM--(BUSINESS WIRE)--Modra Pharmaceuticals B.V. ("Modra") today announced the start of patient treatment in its Phase II...
Read more
Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial

Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors

May 17, 2019
Cristal Therapeutics, a clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and...
Read more
Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors

InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy

May 15, 2019
- Journal of Neuroscience publication demonstrates that antagonizing miR-135a reduces seizures in chronic TLE model -
Read more
InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy

A One-Two Punch for HPV-16-positive Cancers? 30 Apr 2019

April 30, 2019
ISA's phase 2 trial with lead product ISA101
Read more
A One-Two Punch for HPV-16-positive Cancers? 30 Apr 2019

Video interview with ISA CSO Prof. Dr. Cornelis Melief at AACR 2019

April 18, 2019
ecancer interview ISA's Chief Science Officer Prof. Dr. Kees Melief
Read more
Video interview with ISA CSO Prof. Dr. Cornelis Melief at AACR 2019

CRI Speaks with 2019 AACR-CRI Lloyd J. Old Award Recipient, Dr. Cornelis 'Kees' Melief

April 02, 2019
Cornelis J. M. 'Kees' Melief, M.D., Ph.D., received the 2019 AACR-CRI Lloyd J. Old Award in Cancer Immunology presented by the...
Read more
CRI Speaks with 2019 AACR-CRI Lloyd J. Old Award Recipient, Dr. Cornelis 'Kees' Melief

ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019

March 28, 2019
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation
Read more
ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019

Home > Press Releases

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds